Loading company…
Rona Therapeutics develops modular nucleic acid medicines and drug delivery platforms.
Established in 2021 and based in Shanghai, China, Rona Therapeutics researches nucleic acid drugs, including siRNA candidates for metabolic, central nervous system, eye, and tumor conditions. Its platforms target the liver, central nervous system, and other tissues. In March 2025, the company raised USD 25 million in pre-series B funding led by Geuniom Group, with Lilly Asia Ventures, LongRiver Investments, and BioTrack Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in